Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307156 | 0.82 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5578492 | 0.82 | HSD11B1 (0.39) | KMT2AMEN1NR3C1SMN1; SMN2HSD11B1 | |
| SCHEMBL5578579 | 0.77 | HDAC8 (0.35) | KMT2AMEN1HSD11B1 | |
| SCHEMBL5578875 | 0.75 | KMT2A (0.62) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL5582420 | 0.73 | AVPR1A (0.41) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL5578499 | 0.72 | SIGMAR1 (0.53) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5578847 | 0.70 | MAPT (0.50) | KMT2AMEN1AKR1B1SMN1; SMN2HSD11B1 | |
| SCHEMBL5578664 | 0.70 | DRD1 (0.41) | KMT2AMEN1SMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL5579027 | 0.66 | STS (0.48) | KMT2AMEN1HSD11B1POLB | |
| SCHEMBL2316904 | 0.66 | SIGMAR1 (0.47) | KMT2AMEN1CYP2D6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | KMT2A 1940/4885MEN1 882/4885NR3C1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.